Cronos Smashes Records While Facing a Fresh Israeli Dumping Probe

Record revenue, gross profit, and adjusted EBITDA in Q2 as the borderless strategy hits its stride — but a new anti-dumping inquiry and a delayed Dutch acquisition temper the celebration.

CRON.TO · Earnings Call · 2026-08-06

Records on the Back of the Borderless Strategy

Cronos Group delivered a stellar quarter that exceeded even its own optimistic plans. Consolidated net revenue rose 58% year-over-year to $53 million, gross profit nearly doubled to $28.5 million, and adjusted EBITDA hit a record $13.1 million — a swing of +$11.4 million versus Q2 2025. CEO Mike Gorenstein opened the call by touting “organically achieving records across net revenue, gross profit, and adjusted EBITDA” — Michael Gorenstein, Chairman, President, and CEO · 2026-08-06 driven by strength in every market. The growth is increasingly powered by the company's borderless product playbook: taking flagship innovations like Spinach's vapes, edibles, and pre-rolls into new geographies while scaling existing footprints in Canada, Israel, and Germany. A key driver has been the full ramp of the expanded GrowCo cultivation facility, which resolved long-standing supply constraints. In Canada, the Spinach brand extended its vape leadership, and the disposable vape segment jumped to #2 nationally, propelled by the PUFFERZ all-in-one line. Gorenstein credited the disciplined approach to each product launch: "We haven't really rested on the laurels of the brand. Category by category, we focus on each product as if we were launching it new and making sure it's a best-in-class product." International markets outside Israel also surged 88% year-over-year, led by Germany. CFO Anna Shlimak broke down the gross margin expansion into three buckets: better growing conditions, geographic mix toward Israel and other no-excise-tax markets, and the high-margin vape portfolio. She summed it up as "that perfect storm of favorability".

The Reopened Israeli Dumping Investigation: A Shadow Over the Record

While the operational story is undeniably strong, the quarter also brought a significant regulatory headwind. Israel's Trade Levies Commissioner opened a new investigation into alleged dumping of Canadian medical cannabis imports — just months after a previous probe ended without duties. Gorenstein was firm in his response:

We dispute the allegations underlying the investigation. We will cooperate fully with the ministry and are confident the facts support us.
Michael Gorenstein, Chairman, President, and CEO · 2026-08-06

He reiterated that Cronos does not engage in dumping and pointed to the prior investigation where the company provided comprehensive pricing and cost data. This investigation is a company-unique risk, but it's not the first time geopolitics has clouded the Israeli business. Cronos Israel remains a strategic asset, having invested heavily in local infrastructure, and it delivered its 10th consecutive quarter of record net revenue, up 60% y/y. Still, the renewed dumping probe injects uncertainty into a market that contributes materially to the higher-margin mix. Interestingly, the momentum around this theme is visible in the keyword data: "dumping" and "investigation" both spiked to high momentum in Q2 2026, alongside "CanAdelaar" and "Netherlands." The company's own acquisition of CanAdelaar — the Dutch adult-use leader — remains pending regulatory clearance, with Gorenstein noting, "We expect the acquisition to close in the second half of 2026." He stressed that the delay appears to be ordinary course: "based on the information available to us, the timing appears to reflect the ordinary course of the Dutch regulatory review process." In prior calls, management consistently emphasized the strategic logic of entering the Netherlands over Germany, citing the closed supply chain and the adult-use brand leverage. Gorenstein had explained on the May 2026 call: "It's a market that without making an acquisition, we would have no way to get in because it's closed as far as import/export... it is moving directly into the adult-use market." That reasoning remains intact, but the longer the deal drags, the more investors may question whether the regulatory environment in Europe is becoming less hospitable. Balancing these headwinds is a pristine balance sheet: $827 million in cash plus short-term investments, a $60 million share repurchase executed in the quarter, and positive cash flow from operations. The company has no need to raise capital and remains opportunistic. As Gorenstein put it in a prior call, "We don't need to use our stock as currency... we really just focus on what the market opportunity is." Cronos is firing on all cylinders operationally, but the combination of a re-opened Israeli probe and delayed Dutch approval introduces enough uncertainty to keep a lid on enthusiasm. The market will be watching closely whether these regulatory clouds lift as quickly as they appeared.